Fulgent Genetics Receives 'Hold' Rating from Analysts

Genetic testing firm faces mixed analyst reviews amid market uncertainty

Mar. 29, 2026 at 8:19am

Got story updates? Submit your updates here. ›

An extreme close-up of complex genetic testing equipment and instruments, conveying the technical complexity and high-stakes nature of the industry.Fulgent Genetics' advanced genetic testing technology faces an uncertain market outlook as analysts offer mixed reviews.Temple City Today

Fulgent Genetics, Inc. (NASDAQ:FLGT) has received a consensus 'Hold' rating from five analysts covering the stock, with one 'Sell' recommendation, two 'Hold' recommendations, and two 'Buy' recommendations. The average 12-month price target is $32.00.

Why it matters

Fulgent Genetics is a prominent player in the genetic testing and diagnostics industry, which has seen increased demand during the COVID-19 pandemic. Analyst ratings and price targets can significantly impact investor sentiment and the company's stock performance.

The details

Several analysts have recently weighed in on Fulgent Genetics' stock. Zacks Research downgraded the stock from 'Strong Buy' to 'Hold', while Weiss Ratings reaffirmed a 'Sell' rating and Wall Street Zen downgraded the stock from 'Hold' to 'Sell'.

  • Fulgent Genetics reported Q4 2025 earnings on February 27, 2026.

The players

Fulgent Genetics, Inc.

A California-based company specializing in high-complexity genetic testing and diagnostic services, leveraging next-generation sequencing (NGS) technologies and advanced bioinformatics.

Got photos? Submit your photos here. ›

The takeaway

Fulgent Genetics' mixed analyst ratings and uncertain market conditions highlight the challenges facing the genetic testing industry, as companies navigate evolving regulatory environments and shifting consumer demand.